1. Home
  2. World
  3. Novavax Covid vaccine, to be made in India by SII, Shows 90.4% efficacy in US trial

Novavax Covid vaccine, to be made in India by SII, Shows 90.4% efficacy in US trial

By Priyanka Verma 
Updated Date
Novavax Covid vaccine, to be made in India by SII, Shows 90.4% efficacy in US trial

Novavax on Monday announced that its Covid vaccine — NVX-CoV2373 —demonstrated 100% protection against moderate and severe disease with 90.4% efficacy overall in phase-3 trial. “NVX-CoV2373, recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial,” Novavax said in a press statement on June 14.

Also Read :- Covid-19: After 6 days high, India sees a drastic decline in its single day tally

It said the study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

Novavax CEO and President Stanley C. Erck said that Novavax was one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines.

“These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection,” he said.

The Maryland-headquartered company said it intended to apply for regulatory approval by the third quarter of 2021.

Also Read :- Millions forced to stay in-doors as China battles Delta Variant outbreak

After that, it said, it would be on course to make 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines,” said Stanley C. Erck, Novavax’s president and chief executive.

Also Read :- India’s tally sees 3rd Covid wave coming this month, peak in October: Experts

“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.”

While some rich countries have made progress on vaccinating their populations, there remain concerns that many poorer countries are being left out of the global inoculation drive.

Vaccination rates in the world’s poorest nations are far behind the Group of Seven industrialized powers and other wealthy states — in terms of doses administered so far, the imbalance between the G7 and the planet’s low-income countries, as defined by the World Bank, is 73 to one.

Unlike some rival jabs, Novavax’s vaccine — formally known as NVX-CoV2373 — does not have to be stored at ultra-low temperatures.

The company said it was “stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution.”

In theory at least, this means the shots should be more easily transported and administered in countries with less well developed health infrastructures.

Also Read :- K'taka mandates negative test report for all travellers from Maha'tra, Kerala

Further reading:
For the latest news and reviews, follow us on Facebook and Twitter ...
X